Patents by Inventor Masao Seto

Masao Seto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Types of lymphoma and method for prognosis thereof
    Publication number: 20080268453
    Abstract: A method for determining the prognosis of a CD5+DLBCL patient and a CD5-DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13q21.1-q31.3 region is poor; (2) the prognosis of the CD5+DLBCL patient with deletion of 1p36.21-p36.13 region is poor; and (3) the prognosis of the CD5-DLBCL patient with amplification of 5p15.33-p14.2 region is good.
    Type: Application
    Filed: February 6, 2008
    Publication date: October 30, 2008
    Applicants: AICHI PREFECTURE, NGK INSULATORS, LTD.
    Inventors: Masao Seto, Hiroyuki Tagawa, Yasuko Yoshida, Shigeki Kira
  • Methods for Diagnosis and Prognosis of Malignant Lymphoma
    Publication number: 20080004208
    Abstract: In order to more accurately analyze a change in the complicated gene copy number in malignant lymphoma and identify a region affected by an important genomic aberration in greater detail so that the results can be used in diagnosing the type of disease and performing prognosis, genome-wide array CGH is carried out and thus human chromosome 136.23 to p36.32, human chromosome 1 q42.2 to q43, human chromosome 2 p11.2, human chromosome 2 q13, human chromosome 17 p11.2 to p13.3, and human chromosome 19 p13.2 to p13.3 are identified.
    Type: Application
    Filed: December 5, 2005
    Publication date: January 3, 2008
    Applicants: AICHI PREFECTURE, NGK INSULATORS, LTD.
    Inventors: Masao Seto, Hiroyuki Tagawa, Yasuko Yoshida, Shigeki Kira
  • Types of lymphoma and method for prognosis thereof
    Publication number: 20050282177
    Abstract: A method for determining the prognosis of a CD5+DLBCL patient and a CD5?DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13q21.1-q31.3 region is poor; (2) the prognosis of the CD5+DLBCL patient with deletion of 1p36.21-p36.13 region is poor; and (3) the prognosis of the CD5?DLBCL patient with amplification of 5p15.33-p14.2 region is good.
    Type: Application
    Filed: September 22, 2004
    Publication date: December 22, 2005
    Applicants: AICHI PREFECTURE, NGK INSULATORS, LTD.
    Inventors: Masao Seto, Hiroyuki Tagawa, Yasuko Yoshida, Shigeki Kira